Avadel Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Avadel Pharma (AVDL) Tops Q4 EPS by 30c; Reaffirms
March 7, 2017 6:34 AM ESTAvadel Pharma (NASDAQ: AVDL) reported Q4 EPS of $0.00, $0.30 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $43.1 million versus the consensus estimate of $34.95 million.
Total revenues for fourth quarter and full year 2016 were $43.1 million and $150.2 million, compared to $44.6... More